Literature DB >> 25575058

[Activation of Wnt/β-catenin pathway in NK cells by glycogen synthase kinase-3β inhibitor TWS119 promotes the expression of CD62L].

Yongqiang Chen1, Lu Zheng1, Junquan Liu1, Zhonghai Zhou1, Xiaoting Lv1, Juan Zhang1, Song Zhang1, Leiqing Sun1, Fuxing Chen1.   

Abstract

OBJECTIVE: To investigate the effect of Wnt/β-catenin pathway activation by glycogen synthase kinase-3β inhibitor 4,6-disubstituted pyrrolopyrimidine (TWS119) on proliferation and phenotypic characteristics of human nature killer (NK) cells.
METHODS: The peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers and added to the complete medium containing recombinant human interleukin-2 (rhIL-2) and human AB serum to isolate NK cells from PBMCs. After co-cultured with 0-8.0 μmol/L TWS119 for 72 hours, growth curve and Wnt/β-catenin activation of NK cells in each group were determined by CCK-8 and Western blotting. The CD107a and CD62L (L-selectin) expressions in the NK cells were detected using flow cytometry.
RESULTS: NK cells were amplified to (61.76 ± 3.74)% after human PBMCs were cultured for 10 days. The 0-2.0 μmol/L TWS119 could promote the growth of NK cells in a dose-dependent manner, and the proliferation rate gradually dropped when TWS119 was more than 2.0 μmol/L. 0-8.0 μmol/L TWS119 could activate Wnt/β-catenin pathway and up-regulate the expression of CD62L in a dose-dependent manner, but it decreased the expression of CD107a.
CONCLUSION: Human NK cells isolated from peripheral blood treated with TWS119 gave rise to early mature CD62L⁺ NK cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25575058

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  1 in total

1.  GSK-3β as a target for protection against transient cerebral ischemia.

Authors:  Wei Wang; Mingchang Li; Yuefei Wang; Zhongyu Wang; Wei Zhang; Fangxia Guan; Qianxue Chen; Jian Wang
Journal:  Int J Med Sci       Date:  2017-03-11       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.